Final Results of CORE-001: Cretostimogene Plus Pembrolizumab for BCG-Unresponsive NMIBC With CIS

Roger Li, MD, of Moffitt Cancer Center, details the final results of CORE-001, a phase-2, single arm study of cretostimogene grenadenorepvec in combination with pembrolizumab in patients with BCG-unresponsive, non-muscle invasive bladder cancer with carcinoma in situ.

View his further comments on KEYNOTE-057: Outcomes for Patients With BCG-Unresponsive, High-Risk NMIBC Who Do Not Respond to Pembrolizumab.